Chronic myelomonocytic leukemia (CMML) is a myeloproliferative and myelodysplastic neoplasm with few treatment options and dismal prognosis. The role of natural killer (NK) cells and other antileukemic lymphocytes in CMML is largely unknown. We aimed to provide insight into the mechanisms of immune evasion in CMML with a focus on immunosuppressive reactive oxygen species (ROS) formed by the myeloid cell NADPH oxidase-2 (NOX2). The dominant population of primary human CMML cells was found to express membrane-bound NOX2 and to release ROS, which, in turn, triggered extensive PARP-1-dependent cell death in cocultured NK cells, CD8 + T effector memory cells, and CD8 + T effector cells. Inhibitors of ROS formation and scavengers of extracellular ROS prevented CMML cell-induced lymphocyte death and facilitated NK cell degranulation toward Ab-coated, primary CMML cells. In patients with CMML, elevation of immature cell counts (CD34 + ) in blood was associated with reduced expression of several NK cell-activating receptors. We propose that CMML cells may use extracellular ROS as a targetable mechanism of immune escape.
Introduction
Patients with CMML present with elevated monocyte counts in blood (.1 3 10 9 /L), along with the presence of blast cells in blood and bone marrow [1] . CMML typically progresses slowly with signs of myeloproliferation and myelodysplasia. The median survival after diagnosis is ,2 y, with few long-term survivors [2] , which is partly explained by a high risk of transition into AML [3] . Most patients with CMML are older than 60 y and are ineligible for allogeneic bone marrow transplantation, which remains the only potentially curative treatment [4] .
ROS are produced by several types of myeloid cells as a defense strategy against microorganisms. However, ROS formed by the NADPH oxidase/NOX2 of monocytes and granulocytes have also been ascribed a role in immune regulation. Thus, the intact capacity of myeloid cells to produce ROS via NOX2 is reportedly important to dampen the activity of autoreactive T cells [5] . In cancer, the extracellular release of NOX2-derived ROS is associated with significant dysfunction of antineoplastic lymphocytes, in particular, NK cells and subsets of T cells [6] [7] [8] . An inhibitor of NOX2-mediated ROS formation, HDC is used in combination with the NK and T cell-activating cytokine IL-2 for relapse prevention in the postchemotherapy phase of AML [9, 10] . Post hoc analyses of phase III trial results implied that the clinical efficacy of HDC/IL-2 is pronounced among patients with AML of monocytic differentiation in which patients harbor leukemic cells that coexpress a functional NOX2 and H 2 Rs [8, 11] .
For this study, we 1) determined the expression of NOX2 and H 2 Rs on primary human CMML cells, 2) assessed the potential immunosuppressive properties of CMML cells, and 3) determined phenotypes of circulating NK cells and CD8 + T cell subsets from patients with CMML. Our results suggest that NOX2-derived ROS may constitute a targetable mechanism of leukemia-related immunosuppression in CMML.
in bone marrow), whereas 2 (17%) had CMML-2. Ten patients were men and 2 were women (ages 52-88 y; median, 70 y). Absolute counts of circulating monocytes in patients with CMML were available from 9 patients and ranged from 4. 
Isolation of cells
PBMCs from patients and healthy donors were isolated as previously described [12] . In brief, blood samples or buffy coat leukocytes were subjected to density gradient centrifugation after dextran sedimentation. NK cells, CD8 
ROS production
The extracellular ROS production of primary CMML cells was measured by isoluminol-enhanced chemiluminescence as previously described [8] . In brief, 2 3 10 5 cells were added to 96-well plates in the presence of isoluminol (10 mg/ml) and HRP (4 U/ml) and were stimulated with the NOX2 inducer N-formyl-methionyl-leucyl-phenylalanine (0.1 mM). Light emission was recorded using a FLUOstar V platereader (BMG Labtech, Ortenberg, Germany). Assays of NK cell degranulation and Ab-dependent cellular cytotoxicity NK cell degranulation and cytotoxicity against patient-derived, malignant monocytes were assessed in experiments using lintuzumab (AbbVie, Stockholm, Sweden), a humanized anti-CD33 Ab. NK cells from healthy donors were coincubated with monocytes, labeled with CellTrace violet stain (Thermo Fisher Scientific), in the presence of anti-CD107a-PE-Cy7 Abs (BD Pharmingen) and antioxidative compounds for 4 h at 37°C and 5% CO 2 . Thereafter, the cells were stained with LIVE/DEAD fixable dead cell stain and assessed for lysis of monocytes and NK cell degranulation by flow cytometry. For culture experiments, cytotoxicity assays, and confocal microscopy, Iscoves' modified DMEM, supplemented with 10% human AB + serum, was used. 
Lymphocyte cell death

Confocal microscopy
Compounds
The following compounds were used: HDC (100 mM; Sigma-Aldrich, St. Louis, MO, USA), the H 2 R antagonist ranitidine (GlaxoSmithKline, Mölndal, Sweden), AH202399AA (a chemical control to ranitidine; GlaxoSmithKline), catalase (200 U/ml; Sigma-Aldrich), IL-2 (500 U/ml; Chiron, Emeryville, CA, USA), the NOX2-inhibitor DPI [13] (3 mM; Sigma-Aldrich), and the PARP-1 inhibitor PJ34 (0.5 mM; Sigma-Aldrich).
Immunophenotyping by flow cytometry Monocytes and blasts from patients with CMML were analyzed using a panel consisting of anti-CD33 (clone P67.6, PE-Cy7), anti-CD34 (clone 8G12, PE), anti-CD56 (clone NCAM16, PE-Cy7, APC), anti-CD14 (clone MwP9, APCCy7), anti-CD15 (clone HI98, APC), all from BD Pharmingen. Antiflavocytochrome b558 (gp91 phox ) (clone 7D5, FITC). Antihistamine H 2 receptor (polyclonal rabbit IgG) was from MBL International (Woburn, MA, USA), and goat anti-rabbit secondary Ab (PE-Cy5.5) was from Thermo Fisher Scientific.
Statistical analyses and ethical considerations
One-way ANOVA, followed by Bonferroni's posttest, was used for multiple comparisons, and a paired t test was used for single comparisons. P , 0.05 was considered significant. In figures, asterisks are used as follows: *P , 0.05, **P , 0.01, ***P , 0.001. All indicated P values are 2-sided. The study was approved by the Ethical Review board of Gothenburg, and all experiments were performed in accordance with the Declaration of Helsinki.
RESULTS
Monocytic CMML cells express functional NOX2 and H 2 Rs
Immunosuppressive ROS are produced by malignant granulocytes in chronic myeloid leukemia and by malignant monocytic cells in AML [8, 14, 15] , but the potential ROS-forming capacity of primary CMML cells has remained unknown. In initial experiments, we analyzed the production of ROS from human CMML cells, along with their expression of NOX2, as reflected by the MFI of the cell membrane-bound NOX2-specific subunit gp91 phox . The monocytic CD14 + population in peripheral blood from patients with CMML expressed similar levels of gp91 phox as did CD14 + monocytes from healthy donors ( Fig. 1A and B) . The fraction of CD14 + monocytes that were positive for gp91 phox was in excess of 99% for all patients with CMML (data not shown).
Signaling via H 2 Rs has been shown to transduce histamineinduced inhibition of ROS formation [16] . The primary monocytic CMML cells invariably expressed high levels of H 2 Rs, suggesting that NOX2 activity may be targeted by HDC (Fig. 1A and B). Although most CMML cells were CD33 + CD14 + , a smaller population of CD34 + blasts was detected in the blood of most patients. In contrast to the more mature monocytic CMML cells, the CD34 + blast cells expressed low levels of gp91 phox and moderate levels of H 2 Rs (Fig. 1A and B) . To determine whether the expression of gp91 phox reflected a functional NOX2, patient CD14 + cells were sorted by FACS, followed by analysis of ROS production, after stimulation with N-formyl-methionyl-leucylphenylalanine, a formulated tripeptide of bacterial origin that triggers ROS formation in human myeloid cells [17] . The sorted monocytic CMML cells were found to produce high levels of ROS, and the addition of HDC significantly suppressed ROS production ( Fig. 1C and D) . The ROS-inhibitory effect of HDC was, in turn, antagonized by ranitidine, a specific H 2 R antagonist but not by a chemical control to ranitidine, AH202399AA, in which a thioether group has been replaced by an ether, thereby reducing its affinity at H 2 R .50-fold [18] (Fig.  1C and Supplemental Fig. 1 ). These results imply that HDC suppresses NOX2-mediated ROS production in CMML cells by targeting H 2 R.
Inhibition of NOX2 promotes NK cell degranulation and Ab-dependent cellular cytotoxicity toward Ab-coated primary CMML cells Healthy and malignant myeloid cells were previously shown to compromise the antitumor functions of NK cells by producing ROS [16] . We acquired confocal micrographs of interacting primary CD14
+ CMML cells and NK cells in coculture experiments. When analyzing the interaction between CD14 + CMML cells and NK cells, we observed a distinct synapse between cells and a polarization of membrane-bound NOX2 toward the NK cell ( Fig. 2A) . The finding that monocytic CMML cells expressed NOX2 in the proximity of the immunologic synapse, along with their capacity to produced high levels of ROS, incited us to study whether ROS production may constitute a mechanism by which CMML cells escape immune-mediated killing.
To that end, we tested the ability of IL-2-stimulated NK cells to degranulate in response to primary CD14 + CMML cells in the presence or absence of lintuzumab (anti-CD33) as the linking Ab to enhance the interactions between NK cells and CMML cells. NK cells alone displayed little degranulation against primary CMML cells. The addition of lintuzumab significantly augmented NK cell responses (P , 0.01, n = 9), and the addition of the NOX2-inhibitor HDC further enhanced the degranulation response against the primary leukemic cells (P , 0.01, n = 9; Fig. 2B ).
CD14 + CMML cells induce PARP-1-dependent cell death in lymphocytes
In overnight, coculture experiments, primary CD14 + CMML cells triggered significant cell death in healthy NK cells (P , 0.001, n = 6, Fig. 2C ) and CD8 + T cells (P , 0.001, n = 4; Fig. 3A) . The CMML-induced lymphocyte apoptosis was prevented by the NOX2 inhibitors HDC and DPI and by catalase, which scavenges extracellular ROS by degrading H 2 O 2 [19] . Lymphocytes were also rescued from CMML cell-induced cell death by PJ34, an inhibitor of PARP-1, thus suggesting that ROS formed by CMML cells induce PARP-1-dependent cell death, also known as parthanatos [20] , in NK cells and CD8 + T cells (Figs. 2C and 3A ).
CMML cells are preferentially suppressive toward mature T cell subsets
We have previously shown that the presence of CD8 + T EMs is associated with favorable prognosis for patients with AML + and CD34 + cells in peripheral blood from patients with CMML (n = 11) and healthy controls (n = 10). (C) Representative ROS measurement from FACS-sorted CD14 + CMML cells with or without inhibition with HDC (50 mM), ranitidine (10 mM), and AH202399AA (10 mM). (D) Eleven combined experiments using NOX-2 inhibitor HDC (100 mM, P , 0.001), analyzed using Wilcoxon matched-pairs signedrank test.
receiving immunotherapy with HDC/IL-2 for relapse prevention in the postconsolidation phase [21] . To determine whether CMML cells specifically inhibit certain T cell subsets, we used FACS of CD8 + T cell subsets (T Ns , T CMs, T EMs , and T effs ) and cultured these subpopulations overnight with primary monocytic CMML cells. The distribution of CD8 + T cell subsets in blood was similar in patients with CMML and in age-matched healthy control subjects (Supplemental Fig. 2) . The CMML cells predominantly induced cell death in more mature CD8 + T cell subsets, i.e., T EMs and T effs , whereas T Ns were largely resistant to CMML cell-induced apoptosis (Fig. 3B) . The difference in T cell subset apoptosis was predominantly explained by a difference in ROS sensitivity because the NOX2 inhibitor DPI efficiently rescued all T cell subsets from CMML cell-induced apoptosis.
Deficiency of receptor expression in NK cells from patients with CMML
The functions of NK cells are regulated by activating and inhibitory receptors expressed on the NK cell surfaces [22] . Earlier studies show that reduced expression of activating NK cell receptors in myeloid malignancies, including AML and MDS, heralds unfavorable prognosis for survival [23] [24] [25] [26] . In addition, progression of MDS has previously been associated with downmodulation of activating NK cell receptors [25] . When analyzing patients for their percentages of peripheral CD14 2 CD34 + blast cells, we found that the group of patients with a higher proportion of circulating CD34 + blasts (.2% of PBMCs) showed significantly lower intensities of the activating NK cell receptors NKp30, NKp80, and 2B4 as compared with agematched healthy controls (Fig. 4A) . In addition, the frequency of circulating NK cells expressing NKp30, NKp46, NKp80, DNAM1, and 2B4 in blood was lower in patients with CMML than it was in healthy controls (Fig. 4B) . We also cultured PBMCs from patients or healthy donors in the presence or absence of IL-2 for 72 h and determined the expression of NK cell receptors. IL-2 stimulation significantly enhanced the expression of NKp30, NKp46, and DNAM1 in patient-derived NK cells (Supplemental Fig. 3) .
Earlier studies have shown that ROS-producing monocytes down-modulate the expression of activating NK cell receptors in vitro [27] . It has remained unknown, however, whether the observed down-modulation of activating receptors reflects secondary events related to the initiation of NK cell apoptosis rather than direct, ROS-induced reduction of receptor + CMML cells by IL-2-stimulated NK cells (n = 9) in the presence or absence of anti-CD33 Ab lintuzumab (1 mg/ml) and HDC (100 mM). Data were analyzed using Student's paired t test with Bonferroni's correction. (C) NK cell death (n = 6) after overnight incubation with CMML cells at ratios ranging from 16:1 to 1:1 For each donor, the degree of apoptotic NK cells from the first NK:CMML ratio with $50% apoptotic NK cells is shown. When indicated, the NOX2-inhibitor HDC (100 mM), the PARP-1 inhibitor PJ34 (0.5 mM), the NOX2 inhibitor DPI (3 mM), or catalase (200 U/ml) was present during the overnight incubation. The effect of the inhibitors on CMML-induced NK cell apoptosis was analyzed by 1-way ANOVAs, followed by Bonferroni's multiple comparison test. expression by NK cells. We, therefore, exposed NK cells to ROS-producing monocytic cells from healthy donors in the presence of the PARP-1 inhibitor PJ34, which upholds the viability of NK cells despite exposure to ROS [14] . As shown in Fig. 5A , NK cells exposed to monocyte-derived ROS in the presence of PJ34 significantly down-regulated NKp46 and CD16, with a similar trend for NKp80 and DNAM-1. No downregulation of NK cell receptor expression was observed when NK cells were exposed to PJ34 in the absence of ROSproducing cells (data not shown).
DISCUSSION
NK cells and myeloid cells engage in bidirectional crosstalk to initiate immune responses, and NK cells have been proposed to shape, regulate, and terminate immune responses by killing subsets of myeloid cells [28] [29] [30] . NK cells also exert cytotoxicity against several malignant myeloid cells. A deficiency of NK cell function has been proposed to affect the course of disease in myeloid leukemias [10, 23, 26, 31] . For example, low NK cell counts in blood are associated with relapse of leukemia after tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia [32] , and poor NK cell function and deficient expression of activating natural cytotoxicity receptors herald dismal prognoses in patients with AML [23, 24, 31, 33] .
Although details regarding the mechanisms underlying the NK cell deficiency in myeloid malignancies remain to be defined, the NOX2-dependent formation of extracellular ROS from myeloid cells has been proposed as a contributing pathway of immunosuppression [8, 16, 34, 35] . A main finding in this study was that patients with CMML harbor monocytic leukemic cells that express functional NOX2 and that the release of NOX2-derived ROS from leukemic cells triggered dysfunction and cell death in lymphocytes with purported antileukemic function, including NK cells and CD8 + T cells. We also show that strategies to target NOX2-derived ROS, produced by CMML cells, maintained the viability of NK cells and subsets of CD8 + lymphocytes and upheld the antileukemic functions of NK cells. These strategies included degradation of extracellular ROS (catalase) and specific inhibition of NOX2 (DPI) along with HDC, which ligates H 2 R to inhibit NOX2 function.
Relatively few studies have addressed the immunobiology of CMML or the role of antileukemic lymphocytes for the course of disease. In a cohort of 41 patients with MDS (6 with CMML), Carlsten et al. [25] observed that NK cells derived from bone marrow samples displayed reduced cytotoxicity compared with those from age-matched healthy controls. The authors also demonstrated decreased surface expression of activating receptors (DNAM-1 and NKG2D) in patient-derived NK cells, which correlated with elevated bone marrow blast counts [25] . Although the previous study did not allow separate analysis of the NK cell compartment in CMML, the results are compatible with our finding of reduced expression of several activating receptors by NK cells from patients with CMML, in particular, in patients with higher counts of CD14 2 CD34 + blasts in blood. In accordance with previous studies [27] , we observed that ROS produced by monocytic cells induced down-regulation of activating NK cell receptors. Experiments using the PARP-1 inhibitor PJ34 implied that ROS triggered down-regulation of NK cell receptors in the absence of cell death, thus supporting the idea that ROS, rather than cellular events associated with early apoptosis, reduce the expression of activating NK cell receptor expression. Our results also imply that the NK cell receptor deficiency is at least partly reversible by cytokine activation; as shown in Supplemental Fig. 3 , the expression of NKp46, NKp30 and DNAM-1 on NK cells from patients with CMML was restored by IL-2 to MFI levels comparable to those of healthy, agematched donors.
The role of cytotoxic T cells in CMML has not been characterized in detail. Allo-SCT is the only potentially curative treatment in CMML, implying that T cell immunity likely has a role in eliminating malignant cells [2, [36] [37] [38] . This notion is further supported by the clinical efficacy of donor lymphocyte infusion using CD3 + T cells in patients with CMML with relapse after allo-SCT [39] . In the present study, we observed that primary CMML cells triggered significant ROS-dependent apoptosis in the CD8 + T cell compartment, in particular, in the nonnaïve cells that are assumed to mediate clearance of leukemic cells [40] . These findings are compatible with an earlier report showing that CD8 + T EMs are highly sensitive to cell death induced by low levels of exogenous ROS [41] . The mechanisms explaining the differential sensitivity of T cell subsets to CMML cell-derived ROS should be further defined. In addition, further studies are required to clarify whether CMML cell-induced immunosuppression toward T cells affects the course of disease and whether ROS formation by leukemic cells may contribute to the reportedly limited benefit of allo-SCT in CMML [2, 36] .
The NOX2 inhibitor HDC has been shown to prevent relapse of AML when used in conjunction with low-dose IL-2 after the completion of chemotherapy [9] . Post hoc analyses of phase III trial results suggested that the clinical efficacy of HDC/IL-2 is pronounced in patients with AML classes 4 and 5, according to the French-American-British classification [8] . These subtypes of AML contain leukemic populations with monocytic differentiation that carry functional NOX2 with preserved capacity to produce and release ROS along with H 2 Rs [11] . These findings have formed the background to the hypothesis that ROS production by monocytic AML cells may serve as a mechanism of leukemia-induced immune escape [8] . The results of the present study imply that similar immunosuppressive mechanisms may be at work in CMML.
In summary, our results suggest that primary human CMML cells produce immunosuppressive ROS, which may affect NK cell-and T cell-dependent clearance of leukemic cells. We propose that strategies to target extracellular ROS may be of value in ameliorating antileukemic cellular immunity in CMML. 
